PCC-1 / Glenmark - LARVOL DELTA

Novel small molecule HPK1 inhibitor PCC-1 induces strong anti-tumor activity (SITC 2021) - "In addition, using the syngeneic model of MC38 expressing human PD-L1, we present for the first time, the combination efficacy of a HPK1 inhibitor with the clinical ICB, Atezolizumab. Further evaluation of PCC-1 is ongoing to advance towards clinic. Trial Registration N/A"

Oncology • IFNG • PD-L1